VECTUS BIOSYSTEMS LIMITED (ASX: VBS)
Health care · News and insights
Price unavailable
Latest VBS announcements
Announcement Insights
Vectus Advances VB0004 Toward an Australian Trial After Supportive FDA Feedback
Vectus Biosystems has moved its lead idiopathic pulmonary fibrosis drug candidate VB0004 closer to a planned Phase Ib/IIa study, with the FDA’s November 16 written feedback described as supportive and practical. After securing a pre-IND meeting in late October and appointing a clinical-trial adviser in November, the company says it will incorporate the feedback into its Investigational New Drug package, which is now its focus.
Updated 16 Nov 2026, 08:49 AM Sydney time
Sources
FDA Pre-IND feedback for VB0004Appointment of Prof Tamera Corte as Chief Clinical AdvisorNotification regarding unquoted securities - VBSQuarterly Activities & Appendix 4C Cash Flow Reports2026 AGM PresentationsResults of 2026 AGMComments
2026-11-16 · Health care
VBS: $0.053 +0.00% · MC: $4M
Vectus Biosystems says FDA written feedback on its planned VB0004 study for idiopathic pulmonary fibrosis was supportive and provided practical guidance across manufacturing, nonclinical and clinical matters. The company will incorporate the responses into its Investigational New Drug package for a planned Phase Ib/IIa study in Australia; it says completing the package is now its focus.
Updated 2026-11-16 08:41
Sources
FDA Pre-IND feedback for VB0004Comments
2026-11-09 · Health care
VBS: $0.076 +8.57% · MC: $4M
Vectus Biosystems has appointed Professor Tamera Corte, a pulmonary fibrosis specialist and experienced clinical-trial investigator, as Chief Clinical Advisor to guide development of its lead candidate VB0004. The appointment supports preparations for a planned adaptive Phase Ib/IIa trial in idiopathic pulmonary fibrosis; FDA written feedback on the proposed programme is expected by mid-November and is intended to inform the next clinical and regulatory steps.
Updated 2026-11-09 11:50
Sources
Appointment of Prof Tamera Corte as Chief Clinical AdvisorComments
2026-10-30 · Health care
VBS: $0.075 -5.06% · MC: $4M
Vectus Biosystems issued 7.9 million unquoted options, completing the option component of its May placement after shareholders approved the issue at the AGM. The options were issued for no cash consideration and are exercisable at 20 cents until October 2028.
Updated 2026-10-30 18:27
Sources
Notification regarding unquoted securities - VBSComments
2026-10-29 · Health care
VBS: $0.079 +0.00% · MC: $4M
The FDA granted Vectus Biosystems’ request for a pre-IND Type B meeting on VB0004 for idiopathic pulmonary fibrosis, with written feedback expected by mid-November to guide the next clinical and regulatory steps. The company appointed Cardinal Health Regulatory Services to support FDA communications and submissions. Cash on hand fell from approximately $719,000 to $410,000 during the quarter; a research and development tax refund of $208,000 was received in October.
Updated 2026-10-29 17:08
Sources
Quarterly Activities & Appendix 4C Cash Flow ReportsComments
2026-10-28 · Health care
VBS: $0.079 -1.25% · MC: $4M
Vectus Biosystems says it is prioritising idiopathic pulmonary fibrosis for lead drug candidate VB0004 and is building patient data to support its intended partnering strategy; the supplied CEO address is truncated before its full outlook is provided. The company also reported lower operating costs, a recent placement and an R&D tax rebate, while all AGM resolutions were passed, including approvals for a placement facility and employee incentive plan.
Updated 2026-10-28 14:50
Sources
2026 AGM PresentationsResults of 2026 AGMComments
Comments